BioSpace News Archive

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced Late Breaking Oral Communication at CTAD 2019.

With more than 1.3 million members, Superior has become a statewide leader in health care

AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology.

Yet One in Four US Adults at High Risk Do Not Plan to Get Vaccinated This Season

Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety and efficacy data from one of the Company’s two ongoing open label, single arm Phase 1/2 studies of Annamycin for the treatment of relapsed or refractory acute myeloid leukemia (“AML”).

BioIQ, a healthcare engagement and gap closure company, today announced that RTI International (RTI), a leading global research institute, is participating in a round of financing joined by existing investors Savitr Capital, HealthQuest Capital, and Arboretum Ventures.

Foundation Medicine, Inc. today announced it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for Piqray®

Accuray Incorporated (NASDAQ: ARAY) announced today that Stanford University Medical Center has selected a second CyberKnife® M6™ System to expand access to precise radiosurgery treatments to more of their patients.

Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery.

Revance Therapeutics, Inc. announced the pricing of an underwritten public offering of 6,500,000 shares of its common stock at a price to the public of $17.00 per share.